Status:
COMPLETED
Race-related Alternative Splicing: Novel Targets in Prostate Cancer
Lead Sponsor:
Duke University
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of prostate cancer.
- Self-reported race of AA or white.
- Availability of five unstained slides per radical prostatectomy specimen and an associated Hematoxylin and Eosin stained slide for each radical prostatectomy specimen from NC-LA PCaP.
- Classification of prostate cancer of low, intermediate or high aggressiveness, as defined by NC-LA PCaP.
Exclusion
- 1\. Obtained radical prostatectomy tissue is inadequate for RNA analysis and/or is not positive for adenocarcinoma of the prostate of low, intermediate or high aggressiveness.
Key Trial Info
Start Date :
January 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 14 2021
Estimated Enrollment :
169 Patients enrolled
Trial Details
Trial ID
NCT03424213
Start Date
January 30 2018
End Date
July 14 2021
Last Update
February 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710